The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [ICH] Guideline for Good Clinical Practice [GCP] was first produced in June 1996 as an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects.2 While the original ICH GCP still provides an excellent standard for the conduct of clinical trials in humans, the research environment has changed since those guidelines came into effect.
In 2016, ICH GCP – which remained unchanged for 20 years – was updated by means of an addendum, which provides additional guidance without changing the existing text. In this white paper, we will explore the revised guideline and discuss its impact on small biotech and specialty pharma sponsors, with a focus on risk-based approaches to quality management.
Background
Since the introduction of ICH GCP in 1996, the clinical trial landscape has fundamentally changed. Advances in technology – the proliferation of the internet, smartphones, electronic data capture, real-time review of clinical data – have created new opportunities and transformed the drug development process into a truly global enterprise.
Technological progress is, however, counterbalanced by the growing complexity and cost of clinical trials, as well as the increased rigor of ethical and quality standards. Conduct of global clinical trials requires progressively greater division of tasks across multiple functional teams, organizations, and locations. Thus, the current research environment is creating pressure on sponsors, particularly resource-constrained small biotech and specialty pharma companies.
To read more, download the complete white paper by submitting the white paper on this page.
International Council for Harmonisation E6[R2] addendum: Challenges of implementation
Arun Bhatt. Perspect Clin Res. 2017 Oct-Dec.
Free PMC article
Abstract
The International Council for Harmonisation [ICH] E6 - good clinical practice [GCP] [R2] addendum - was released in 2016 to encourage implementation of improved approaches for the management of clinical trials. The changes in different sections include new approaches - quality management system, risk-based monitoring with emphasis on human subject protection, and data integrity. The article discusses challenges in adoption and implementation of the changes in ICH GCP guideline for clinical trial stakeholders.
Keywords: Addendum; International Council for Harmonisation; investigator; regulatory; sponsor.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development.
Bhagat R, Bojarski L, Chevalier S, Görtz DR, Le Meignen S, Makowski M, Nadolny P, Pillwein M, Suprin M, Turri S. Bhagat R, et al. Ther Innov Regul Sci. 2021 Mar;55[2]:251-261. doi: 10.1007/s43441-020-00209-0. Epub 2020 Sep 3. Ther Innov Regul Sci. 2021. PMID: 32885397 Free PMC article.
Stakeholders' recommendations for revising Good Clinical Practice.
Corneli A, Forrest A, Swezey T, Lin L, Tenaerts P. Corneli A, et al. Contemp Clin Trials Commun. 2021 Apr 16;22:100776. doi: 10.1016/j.conctc.2021.100776. eCollection 2021 Jun. Contemp Clin Trials Commun. 2021. PMID: 33997463 Free PMC article.
Stakeholders' views on the most and least helpful aspects of the ICH E6 GCP guideline and their aspirations for the revision of ICH E6[R2].
Dombeck C, Swezey T, Forrest A, Tenaerts P, Corneli A. Dombeck C, et al. Contemp Clin Trials Commun. 2022 Aug 17;29:100983. doi: 10.1016/j.conctc.2022.100983. eCollection 2022 Oct. Contemp Clin Trials Commun. 2022. PMID: 36111176 Free PMC article.
General Principles for the Education and Training of GCP Inspectors: The Outcome of Discussions by International Regulatory Experts in the Discussion Group on the ICH E6 Guideline.
Uyama Y, Yamazaki E, Clark K, Wang CY, Woro E, Tong FY, Sachidanandan S, Rodriguez A, Oh H, Saleh K, Cirunay J, Wapeewuttikorn A, Rogov E, Alshahwan KW, Herrera I, Mthetwa J, Fakudze F, Osawa T. Uyama Y, et al. Ther Innov Regul Sci. 2015 Mar;49[2]:249-253. doi: 10.1177/2168479014551646. Ther Innov Regul Sci. 2015. PMID: 30222411
[ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
Englev E, Petersen KP. Englev E, et al. Ugeskr Laeger. 2003 Apr 14;165[16]:1659-62. Ugeskr Laeger. 2003. PMID: 12756823 Review. Danish.
Cited by
Identification of Lifestyle Risk Factors in Adolescence Influencing Cardiovascular Health in Young Adults: The BELINDA Study.
Morcel J, Béghin L, Michels N, Vanhelst J, Labreuche J, Drumez E, Polito A, Ferrari M, Censi L, Deplanque D, Miguel-Berges ML, De Ruyter T, De Henauw S, Moreno LA, Gottrand F. Morcel J, et al. Nutrients. 2022 May 17;14[10]:2089. doi: 10.3390/nu14102089. Nutrients. 2022. PMID: 35631230 Free PMC article.
Feasibility and acceptability of a structured quality by design approach to enhancing the rigor of clinical studies at an academic health center.
Moradi H, Schneider M, Streja E, Cooper D. Moradi H, et al. J Clin Transl Sci. 2021 Aug 13;5[1]:e175. doi: 10.1017/cts.2021.837. eCollection 2021. J Clin Transl Sci. 2021. PMID: 34849251 Free PMC article.
The new Good Clinical Practice-2020 in China: Views from ethical perspective.
Yang F, Heng J, Li K, Wang J. Yang F, et al. Lancet Reg Health West Pac. 2021 Mar 2;8:100117. doi: 10.1016/j.lanwpc.2021.100117. eCollection 2021 Mar. Lancet Reg Health West Pac. 2021. PMID: 34327433 Free PMC article. No abstract available.
Sensory Stimulation of the Foot and Ankle Early Post-stroke: A Pilot and Feasibility Study.
Aries AM, Pomeroy VM, Sim J, Read S, Hunter SM. Aries AM, et al. Front Neurol. 2021 Jul 5;12:675106. doi: 10.3389/fneur.2021.675106. eCollection 2021. Front Neurol. 2021. PMID: 34290663 Free PMC article.
Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis.
Kiss S, Németh D, Hegyi P, Földi M, Szakács Z, Erőss B, Tinusz B, Hegyi PJ, Sarlós P, Alizadeh H. Kiss S, et al. BMJ Open. 2021 May 19;11[5]:e042374. doi: 10.1136/bmjopen-2020-042374. BMJ Open. 2021. PMID: 34011580 Free PMC article.
References
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. [Last accessed on 2016 Dec 15]. Available from: //www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Ef... .
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. [Last accessed on 2017 Jul 30]. Available from: //www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Eff... .
- US FDA Guidance for Industry Investigator Responsibilities – Protecting the Rights, Safety, and Welfare of Study Subjects. 2009. Oct, [Last accessed on 2009 Oct 29]. Available from: //www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati... .
- European Medicines Agency Reflection Paper on Risk Based Quality Management in Clinical Trials. 2013. [Last accessed on 2017 Aug 05]. Available from: //www.ema.europa.eu/docs/en_GB/document_library//11/WC500155491.pdf .
- Shuchman M. Commercializing clinical trials – risks and benefits of the CRO boom. N Engl J Med. 2007;357:1365–8. - PubMed
LinkOut - more resources
Full Text Sources
- Europe PubMed Central
- Medknow Publications and Media Pvt Ltd
- PubMed Central
Other Literature Sources
- scite Smart Citations